Dalan Animal Health, Inc., a Los Angeles, CA-based biotech company developing vaccines for new age production animals, raised $1.9m in seed funding.
The company intends to use the funds to launch a honeybee vaccine targeting American Foulbrood, a contagious disease threatening beehives worldwide, and further advance a pipeline of novel vaccines for other new production animals. Dalan recently completed safety and efficacy testing on its first product and will submit a license application for the conditional approval of the vaccine this fall.
Led by CEO Annette Kleiser, the company is currently operating virtually, partnering with laboratories in Europe and the U.S. and is planning to transition to a fully integrated company over the coming 18 months. Dalan will expand its product development to other underserved industries such as shrimp, mealworms and grasshoppers used in feed and food production.
The strategic board of directors and investors include Neal Carter, President Okanagan Specialty Fruits, Linda Rhodes, Animal Health Executive and former founder of Aratana, Petteri Saarinen, CEO LEDiL Oy, Peter Brons-Poulsen, President Colgate Palmolive Europe, and Annette Kleiser, CEO of Dalan.
FinSMEs
06/10/2021